Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry
Real-world analysis shows anti-thymocyte globulin leads to long-term success in aplastic anaemia patients, suggesting efficacy across ages.
Key Points
This analysis aimed to evaluate the long-term success of anti-thymocyte globulin (ATG)-based treatment in aplastic anaemia patients across different age groups.
Evaluated 127 consecutive patients from the Dutch adult aplastic anaemia registry.
Assessed long-term treatment success using a multi-state model.
Defined Transplantation-, Treatment- and Disease-Free Survival (TT-DFS) as the treatment endpoint.
Overall survival at 5 years was 79%.
Probability of TT-DFS was 42% at 5 years post-treatment.
TT-DFS rates were 58% for patients under 40 years and 34% for those 60 years and older.
Older age, severe aplastic anaemia, and absence of a PNH-clone reduced likelihood of reaching TT-DFS.